Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2024-04-26 Regulatory Filings
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a penalty order received from a tax authority and provides details of the event as required by SEBI regulations. The document does not contain financial statements or detailed financial analysis but is a regulatory announcement about a legal/tax matter. It is relatively short (3615 characters) and serves as a disclosure notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-26 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the assignment of credit ratings by a credit rating agency (Care Ratings Limited) for certain financial instruments of the company. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure obligations. The content is an update on credit rating assignments, which is a type of capital/financing update rather than a full financial report or earnings release. The document length is short (1617 characters) and it does not contain financial statements or detailed financial analysis, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement or a regulatory filing in the fallback sense, but a specific update on financing-related information. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-04-25 English
Updates
M&A Activity Classification · 95% confidence The document is an update regarding a Scheme of Arrangement for amalgamation involving Mankind Pharma Limited and other companies. It references filings with the National Company Law Tribunal and mentions a First Motion Application and an upcoming Second Motion Application. The document is a communication to stock exchanges providing an update on the status of a legal and corporate restructuring process. It does not contain financial statements, detailed financial data, or full report content. It is an announcement about the progress of a merger-related legal process rather than the merger filing itself or a detailed merger document. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2024-04-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming no requests for dematerialization/rematerialization of shares for the quarter ended March 31, 2024. It is a compliance certificate issued by the Registrar and Share Transfer Agent and signed by the Company Secretary. The document length is short (2006 characters) and it does not contain financial statements or substantive financial data. It is primarily a regulatory compliance certificate rather than a financial report or announcement of voting results or capital changes. Therefore, it fits best under Regulatory Filings (RNS) as a certification and compliance document.
2024-04-03 English
Acquisition
Regulatory Filings Classification · 95% confidence The document is a formal announcement dated April 2, 2024, from Mankind Pharma Limited addressed to stock exchanges regarding the outcome of a Board Meeting. The key points include approval of a slump sale of the OTC Business to a wholly owned subsidiary to be incorporated, and the incorporation of that subsidiary. The document includes detailed disclosures as per SEBI regulations about the transaction, the business involved, and the subsidiary to be formed. There are no financial statements or detailed financial performance data presented; rather, it is a regulatory disclosure about corporate actions and related party transactions. The document is not an annual or interim report, earnings release, or audit report. It is not a call transcript or investor presentation. It is a regulatory announcement about corporate restructuring and related party transactions, consistent with a Regulatory Filings (RNS) classification. The document length (10,706 characters) and content support that it is a substantive regulatory announcement rather than a brief report publication announcement or a simple notice. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-04-02 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on April 2, 2024, by Mankind Pharma Limited. It discusses the approval of a slump sale of the OTC Business to a wholly owned subsidiary to be incorporated, along with detailed disclosures as per SEBI regulations. The content includes specifics about the transaction, regulatory compliance, and business rationale. There are no financial statements or comprehensive financial performance data presented, nor is this a transcript or presentation. The document is a formal regulatory announcement about corporate actions decided by the Board, specifically related to restructuring and subsidiary incorporation. This fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure and business operations through the creation of a subsidiary and transfer of business units. The document length (over 10,000 characters) and detailed disclosures confirm it is not a mere announcement of a report but a substantive update on financing and corporate structure.
2024-04-02 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.